Cargando…

The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study

BACKGROUND: Minimal hepatic encephalopathy (MHE) is clinically undetectable and the diagnosis requires psychometric tests. However, a lack of clarity exists as to whether the tests are in fact able to detect changes in cognition. AIM: To examine if the continuous reaction time test (CRT) can detect...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauridsen, M. M., Mikkelsen, S., Svensson, T., Holm, J., Klüver, C., Gram, J., Vilstrup, H., Schaffalitzky de Muckadell, O. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636096/
https://www.ncbi.nlm.nih.gov/pubmed/29020023
http://dx.doi.org/10.1371/journal.pone.0185412
_version_ 1783270383513763840
author Lauridsen, M. M.
Mikkelsen, S.
Svensson, T.
Holm, J.
Klüver, C.
Gram, J.
Vilstrup, H.
Schaffalitzky de Muckadell, O. B.
author_facet Lauridsen, M. M.
Mikkelsen, S.
Svensson, T.
Holm, J.
Klüver, C.
Gram, J.
Vilstrup, H.
Schaffalitzky de Muckadell, O. B.
author_sort Lauridsen, M. M.
collection PubMed
description BACKGROUND: Minimal hepatic encephalopathy (MHE) is clinically undetectable and the diagnosis requires psychometric tests. However, a lack of clarity exists as to whether the tests are in fact able to detect changes in cognition. AIM: To examine if the continuous reaction time test (CRT) can detect changes in cognition with anti-HE intervention in patients with cirrhosis and without clinically manifest hepatic encephalopathy (HE). METHODS: Firstly, we conducted a reproducibility analysis and secondly measured change in CRT induced by anti-HE treatment in a randomized controlled pilot study: We stratified 44 patients with liver cirrhosis and without clinically manifest HE according to a normal (n = 22) or abnormal (n = 22) CRT. Each stratum was then block randomized to receive multimodal anti-HE intervention (lactulose+branched-chain amino acids+rifaximin) or triple placebos for 3 months in a double-blinded fashion. The CRT is a simple PC-based test and the test result, the CRT index (normal threshold > 1.9), describes the patient’s stability of alertness during the 10–minute test. Our study outcome was the change in CRT index in each group at study exit. The portosystemic encephalopathy (PSE) test, a paper-and-pencil test battery (normal threshold above -5), was used as a comparator test according to international guidelines. RESULTS: The patients with an abnormal CRT index who were randomized to receive the active intervention normalized or improved their CRT index (mean change 0.92 ± 0.29, p = 0.01). Additionally, their PSE improved (change 3.85 ± 1.83, p = 0.03). There was no such effect in any of the other study groups. CONCLUSION: In this cohort of patients with liver cirrhosis and no manifest HE, the CRT identified a group in whom cognition improved with intensive anti-HE intervention. This finding infers that the CRT can detect a response to treatment and might help in selecting patients for treatment.
format Online
Article
Text
id pubmed-5636096
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56360962017-10-30 The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study Lauridsen, M. M. Mikkelsen, S. Svensson, T. Holm, J. Klüver, C. Gram, J. Vilstrup, H. Schaffalitzky de Muckadell, O. B. PLoS One Research Article BACKGROUND: Minimal hepatic encephalopathy (MHE) is clinically undetectable and the diagnosis requires psychometric tests. However, a lack of clarity exists as to whether the tests are in fact able to detect changes in cognition. AIM: To examine if the continuous reaction time test (CRT) can detect changes in cognition with anti-HE intervention in patients with cirrhosis and without clinically manifest hepatic encephalopathy (HE). METHODS: Firstly, we conducted a reproducibility analysis and secondly measured change in CRT induced by anti-HE treatment in a randomized controlled pilot study: We stratified 44 patients with liver cirrhosis and without clinically manifest HE according to a normal (n = 22) or abnormal (n = 22) CRT. Each stratum was then block randomized to receive multimodal anti-HE intervention (lactulose+branched-chain amino acids+rifaximin) or triple placebos for 3 months in a double-blinded fashion. The CRT is a simple PC-based test and the test result, the CRT index (normal threshold > 1.9), describes the patient’s stability of alertness during the 10–minute test. Our study outcome was the change in CRT index in each group at study exit. The portosystemic encephalopathy (PSE) test, a paper-and-pencil test battery (normal threshold above -5), was used as a comparator test according to international guidelines. RESULTS: The patients with an abnormal CRT index who were randomized to receive the active intervention normalized or improved their CRT index (mean change 0.92 ± 0.29, p = 0.01). Additionally, their PSE improved (change 3.85 ± 1.83, p = 0.03). There was no such effect in any of the other study groups. CONCLUSION: In this cohort of patients with liver cirrhosis and no manifest HE, the CRT identified a group in whom cognition improved with intensive anti-HE intervention. This finding infers that the CRT can detect a response to treatment and might help in selecting patients for treatment. Public Library of Science 2017-10-11 /pmc/articles/PMC5636096/ /pubmed/29020023 http://dx.doi.org/10.1371/journal.pone.0185412 Text en © 2017 Lauridsen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lauridsen, M. M.
Mikkelsen, S.
Svensson, T.
Holm, J.
Klüver, C.
Gram, J.
Vilstrup, H.
Schaffalitzky de Muckadell, O. B.
The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study
title The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study
title_full The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study
title_fullStr The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study
title_full_unstemmed The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study
title_short The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study
title_sort continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—a pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636096/
https://www.ncbi.nlm.nih.gov/pubmed/29020023
http://dx.doi.org/10.1371/journal.pone.0185412
work_keys_str_mv AT lauridsenmm thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT mikkelsens thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT svenssont thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT holmj thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT kluverc thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT gramj thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT vilstruph thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT schaffalitzkydemuckadellob thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT lauridsenmm continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT mikkelsens continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT svenssont continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT holmj continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT kluverc continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT gramj continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT vilstruph continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy
AT schaffalitzkydemuckadellob continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy